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Background: Patient genetic heterogeneity renders it difficult to discover disease-cause genes. Whole-exome
sequencing is a powerful new strategy that can be used to this end. The purpose of the present study was to identify
a hitherto unknown mutation causing autosomal recessive nonsyndromic hearing loss (ARNSHL) in Korean families.
Methods: We performed whole-exome sequencing in 16 individuals from 13 unrelated small families with ARNSHL.
After filtering out population-specific polymorphisms, we focused on known deafness genes. Pathogenic effects of the
detected mutations on protein structure or function were predicted via in silico analysis.
Results: We identified compound heterozygous CDH23 mutations in hearing-loss genes of two families. These include
two previously reported pathological mutations, p.Pro240Leu and p.Glu1595Lys, as well as one novel mutation,
p.Asn342Ser. The p.Pro240Leu mutation was found in both families. We also identified 26 non-synonymous variants in
CDH23 coding exons from 16 hearing-loss patients and 30 Korean exomes.
Conclusion: The present study is the first to show that CDH23 mutations cause hearing loss in Koreans. Although the
precise contribution made by such mutations needs to be determined using a larger patient cohort, our data indicate
that mutations in the CDH23 gene are one of the most important causes of non-syndromic hearing loss in East Asians.
Further exome sequencing will identify common mutations or polymorphisms and contribute to the molecular diagnosis
of, and development of new therapies for, hereditary hearing loss.
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Hearing loss is one of the common heterogeneous disor-
ders. Genetic factors account for more than 50% of cases
of congenital hearing loss, where the majority of cases
exhibit autosomal recessive inheritance [1]. To date, more
than 100 mapped loci have been reported, and 55 non-
syndromic hearing loss genes have been identified (http://
hereditaryhearingloss.org/).
The gene most commonly involved in hearing loss
worldwide is GJB2 [2], while SLC26A4 is also frequently
involved in congenital hearing impairment. The GJB2* Correspondence: skkoo@nih.go.kr
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unless otherwise stated.and SLC26A4 genes make mutation screening relatively
easier, and many studies have focused on only these two
genes. However, in many ethnic populations, GJB2 and
SLC26A4 are responsible for only a small percentage of
deafness cases [3], and screening of mutations in a large
number of genes simultaneously is difficult. Also, it is
near-impossible to identify pathogenic mutations by trad-
itional linkage analysis when DNA is available from only
small families.
Mutations in the CDH23 gene are known to be re-
sponsible for both Usher syndrome type ID (USH1D)
and non-syndromic hearing loss (DFNB12). To date, more
than 50 mutations have been reported in patients with
Usher syndrome type I (USH1D) who have congenital
hearing loss, retinitis pigmentosa (RP), and vestibular
dysfunction. A total of 24 mutations have been reportedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[4]. A genotype-phenotype correlation study suggested
that USH1D was usually associated with nonsense, whereas
DFNB12 with missense mutations [5]. Deafness caused by
CDH23 has been found in many populations worldwide,
including African–American, Dutch, European, German,
Pakistani, Turkish, and Japanese populations [6]. However,
clinical application of CDH23 mutation detection has
lagged because of the size of the gene.
Recent advances in DNA enrichment and next-gener
ation sequencing (NGS) technology have allowed rapid
and cost-effective analysis of the causative mutations of
human disorders, especially those that are heterogeneous
in nature [7]. The techniques are particularly applicable
to analysis of small families [8]. In the present study,
we applied whole-exome sequencing (WES) to study small
Korean families negative for mutations in GJB2 and SLC
26A4, and we identified CDH23 mutations in two fam-




We performed whole-exome sequencing on 16 affected
individuals from 13 families with recessive nonsyndromic
hearing loss (Additional file 1: Figure S1 and Additional
file 2: Figure S2). All affected individuals had early onset
disease and bilateral severe-to-profound hearing loss with-
out additional symptoms (thus, no vestibular dysfunction
was evident), and were members of families that were too
small to allow performance of linkage analysis. Informed
consent was obtained from all participants, and the Insti-
tutional Review Board of the Korea National Institutes of
Health (NIH) approved this study. Genomic DNA was
extracted from peripheral blood samples using a Flexi-
Gene DNA extraction kit (QIAGEN, Hilden, Germany).
Probands from each family were found to be negative for
GJB2 and SLC26A4 mutations based on Sanger sequencing.
Whole-exome sequencing
Whole exons were captured on the SeqCap EZ Human
Exome Library v2.0 (Roche/NimbleGen, Madison, WI,
USA) using 5 μg of genomic DNA. Captured libraries were
sequenced using the Solexa GAIIx Genome Analyzer with
78-bp paired-end reads (SR-106) and the Illumina HiSeq
2000 system with 101-bp paired-end reads (SR-209) accord-
ing to the manufacturers’ protocols. Reads were mapped to
the reference human genome (GRCh37, UCSC hg19) using
the Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.
net/). Single-nucleotide variants (SNVs) and insertions-
deletions (indels) were called using SAMtools (http://sam
tools.sourceforge.net/), based on filtered variants with a
mapping quality score of ≥20, and were annotated using
ANNOVAR (http://www.openbioinformatics.org/annovar/).Mutations identified by exome sequencing were confirmed
by Sanger sequencing and additional control individuals
were genotyped with the aid of TaqMan SNP Genotyping
Assays.
In silico analysis
Evolutionary conservation of the sequences and structures
of the proteins and nucleic acids was assessed using the
ConSeq server (http://conseq.tau.ac.il/). The effect of the
identified novel missense mutation was assessed using
SIFT (http://sift.jcvi.org), PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2/index.shtml) and MUpro (http://mupro.
proteomics.ics.uci.edu/), automatic tools for prediction of
the possible impact of an amino acid substitution on the
structure and function of a human protein. The 3D mo-
lecular structure of the extracellular domain of CDH23
was modeled using I-TASSER (http://zhanglab.ccmb.med.
umich.edu/I-TASSER/). Predicted models were found to
satisfy with quality criteria, such as C-score and TM-score.




We found compound heterozygous mutations in the
CDH23 from two families, SR-106 and SR-209 by whole
exome sequencing (Additional file 1: Figure S1). Table 1
shows the clinical characteristics of the three affected
members in these families. All of them have early onset
and profound hearing loss (see audiogram in Additional
file 1: Figure S1). No patient had any other neurological
signs (vestibular dysfunction and vertigo). The results of ex-
ome sequencing of the two families are shown in Additional
file 3: Table S1. The average number of observed variants
per sample was 59,589. Approximately 10,284 variants were
identified among the coding non-synonymous variants.
Further filtering of common variants using Korean ex-
ome data, which included exome data for 30 Koreans
from another study [9], and from the Korean genome
database TIARA [10] and dbSNP131, reduced to about
529 the number of variants in each sample.
Identification of causative mutations
We focused on 55 known deafness genes (Additional file 3:
Table S2), and three to four candidate variants remained in
each family. Among them, SR-106 family carried two vari-
ants in the CDH23 gene (Additional file 3: Table S3). Two
missense mutations, p.Pro240Leu and p.Glu1595Lys, were
identified to be compound heterozygous mutations in the
proband of SR-106 family. p.Pro240Leu was confirmed
in the patient’s father by Sanger sequencing (Figure 1A).
We subsequently sequenced the entire missing region
(read depth <5) in all 69 exons of CDH23; however, no
other mutation was detected. SR-209 family carried two





















Profound N.D. N.D. 3 3 None N.D.
SR-209 NR at 90
dB nHL





115 Profound 107.3 (L) NR (L) 1.3 1.3 CI ㅡ
N.D., Not Determined; CI, cochlear implant.
*Average of 500, 1000, 2000, and 4000 Hz.
**Average of 125, 250, and 500 Hz.
***Average of 2000, 4000, and 8000 Hz.
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Both variants were also found in an affected sibling and
p.Pro240Leu was confirmed in the father by Sanger se-
quencing (Figure 1B). Additionally, we screened for the
three mutations mentioned above in 93 Korean patients
with hearing loss by Sanger sequencing. Two patients and
one patient were heterozygous for p.Pro240Leu (2.15%)
and p.Glu1595Lys (1.07%), respectively. Direct sequencing
was used to genotype ethnicity-matched negative controlsFigure 1 Confirmation of pathogenic variants in CDH23. (A) Causative
families of affected patients. In family SR-106, compound heterozygous mutat
p.Pro240Leu mutation was confirmed in the father. (B) In family SR-209, comp
carried by an affected sibling and a heterozygous p.Pro240Leu mutation by th
The corresponding DNA sequences appear in red.(over 700). The mutations p.Asn342Ser and p.Glu1595Lys
were absent in all controls, and p.Pro240Leu was detected
in 2 (0.24%) of 818 Korean controls (Table 2).
In silico analysis of CDH23 mutations
We identified three CDH23 mutations, comprising two
previously reported pathological mutations, p.Pro240Leu
and p.Glu1595Lys, and one novel mutation, p.Asn342Ser
(Table 2). The ConSeq server revealed that all of themutations were confirmed by capillary sequencing of DNA from the
ions, p.Pro240Leu and p.Glu1595Lys, were identified. One heterozygous
ound heterozygous mutations, p.Pro240Leu and p.Asn342Ser, were
e father. All pathogenic variants occurred at a highly conserved position.







In silico analysis Family Controls Reference
SIFT/Score1 PolyPhen-22 MUpro3
c.C719T p.Pro240Leu 8 EC3 ㅡ DAMAGING/0.02 0.999 −1 SR-106, SR-209 2/818 [5]
c.A1025G p.Asn342Ser 11 EC3 DXNDN DAMAGING/0 0.905 −1 SR-209 0/707 Novel
c.G4783A p.Glu1595Lys 36 EC15 DRE DAMAGING/0 0.987 −1 SR-106 0/707 [6]
1Prediction of a change being damaging (<0.05) or tolerated.
2Prediction of a change being damaging (>0.85), possibly damaging (0.15-0.85) or benign (<0.15).
3Prediction of a change decreasing protein stability (<0) or increasing protein stability (>0) (confidence score between −1 and 1).
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(Figure 1). Figure 2 shows the locations of these mutations
in a 3D model of the extracellular cadherin (EC) domains.
Mutated EC domains containing residues Asn342 and
Glu1595 are part of the highly conserved calcium-binding
motifs (LDRE and DXNDN) of EC3 and EC15, located in
the region linking cadherin repeats (Figure 2). Calcium
ions are usually bound by six or seven oxygen atoms. Loss
of one of these oxygens normally reduces calcium binding
below the threshold of detection. The p.Glu1595Lys muta-
tion reduces the numbers of oxygen atoms binding
calcium. Such mutations are likely to impair the inter-
action of CDH23 either with itself or other proteins.
Within the polar and uncharged amino acids themselves,
the p.Asn342Ser mutation involves the change from a
small and hydrophilic asparagine into a very small and
neutral serine. The slight difference in length and bulkinessFigure 2 Molecular modeling of CDH23 extracellular domains 3 and 1
domains. Overall, the structure of all predicted 3D models reveals a typical
residues Pro240 and Asn342 are located in EC3. (C, D) Amino acid residue
and those of B and D are mutant. The p.Asn342Ser in EC3 and p.Glu1595Ly
sites (purple) in the linker region between cadherin repeats.of the side chain may influence the steric hindrance be-
tween neighboring residues [11]. Thus it probably de-
creases calcium affinity and impairs protein function
like p.Glu1595Lys. The p.Pro240Leu mutation does not
directly interfere with calcium-binding. However, the
distinctive cyclic structure of the proline side chain im-
parts more conformational rigidity than is afforded by
other amino acids. The leucine side chain is longer and
more flexible (Figure 2). Thus, the p.Pro240Leu substitution
may affect protein stability and, consequently, function. All
of alterations were predicted by Polyphen-2 and SIFT to
pathogenically affect protein structure or function. MUpro
predicted that they decrease protein stability (Table 2).
Identification of CDH23 polymorphism
In addition to these causative mutations, 26 non-
synonymous variants were identified in the CDH23 coding5. Cadherin-23 contains conserved extracellular cadherin (EC) repeat
folding pattern with several beta strands (yellow). (A, B) Amino acid
Glu1595 is located in EC15. The structures of A and C are wild-type
s in EC15 are associated with highly conserved EC calcium-binding
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trol exomes (Table 3). Among them, 18 variants were
reported, of which eight are novel. They also included four
variants (Chr10:73337715, Chr10:73405729, Chr10:7355
8128, and Chr10:73567365) that have potential pathogen-
icity. They were found in hearing loss families but were not
determined to be causative genes in this study.
Discussion
We identified three CDH23 mutations, p.Pro240Leu,
p.Glu1595Lys, and p.Asn342Ser, in 2 (15%) of 13 Korean
families with ARNSHL by whole-exome sequencing. The
present report is the first to demonstrate that CDH23
is an important causative gene for ARNSHL in Korean
patients. Additionally, we screened for eight mutations,








1 Chr10:73337715 9 c.798delA p.Gly266fs
2 Chr10:73377097 11 c.G1081T p.Ala361Ser
3 Chr10:73405717 12 c.G1270A p.Val424Met
4 Chr10:73405729 12 c.G1282A p.Asp428Asn
5 Chr10:73434888 14 c.G1469C p.Gly490Ala
6 Chr10:73434906 14 c.G1487A p.Ser496Asn
7 Chr10:73464825 24 c.G2891A p.Arg964Gln2
8 Chr10:73466729 25 c.G3029A p.Arg1010His
9 Chr10:73472553 27 c.G3352A p.Gly1118Ser2
10 Chr10:73492032 31 c.T4004C p.Val1335Ala
11 Chr10:73492079 31 c.A4051G p.Asn1351Asp
12 Chr10:73498355 33 c.G4310A p.Arg1437Gln
13 Chr10:73501595 36 c.C4762T p.Arg1588Trp
14 Chr10:73501556 36 c.G4723A p.Ala1575Thr
15 Chr10:73537614 37 c.G5023A p.Val1675Ile
16 Chr10:73544086 40 c.G5411A p.Arg1804Gln
17 Chr10:73544093 40 c.C5418G p.Asp1806Glu
18 Chr10:73550117 44 c.C5996G p.Thr1999Ser
19 Chr10:73550969 45 c.G6130A p.Glu2044Lys
20 Chr10:73558128 48 c.G6847A p.Val2283Ile3
21 Chr10:73558886 49 c.G7073A p.Arg2358Gln
22 Chr10:73558952 49 c.C7139T p.Pro2380Leu
23 Chr10:73562763 52 c.A7591G p.Met2531Val
24 Chr10:73567365 57 c.T8401G p.Phe2801Val3
25 Chr10:73571307 62 c.G9238A p.Ala3080Thr
26 Chr10:73571765 64 c.T9373C p.Phe3125Leu
1Exome data for 30 or 128 Koreans from another study.
2Rule out non-segregation.
3Reported as a variant with uncertain pathogenic.p.Glu1595Lys) detected in the present study, and five
others (p.Arg301Gln, p.Glu956Lys, p.Arg1417Trp, p.
Gln1716Pro, and p.Arg2029Trp) that occur at relatively
high frequencies (patient allele frequency > 0.1) in Japanese
patients [4], in 93 unrelated Korean hearing loss patients.
Two patients and one patient, respectively, were heterozy-
gous for p.Pro240Leu and p.Glu1595Lys, and no other mu-
tation was detected. p.Pro240Leu was reported in Japanese
families with ARNSHL as a compound heterozygous
or homozygous mutation [5]. Miyagawa et al. reported
that mutations of the CDH23 gene are important causes
of non-syndromic hearing loss and that p.Pro240Leu
accounted for nearly 43.3% (45/105) of all CDH23-
mutated families in Japanese [4]. In this study, both
families with ARNSHL caused by CDH23 mutations car-






. 1 (SR-255S) 0/128 Novel
. . 1/30 Novel
rs2305207 . 1/30 rs2305207
rs188376296 1 (SR-68) 2/128 rs188376296
rs1227049 8 14/30 [5]
rs10999947 7 54/128 [5]
. 1 (SR-153) 0/128 Novel
. . 1/30 Novel
. 1 (SR-931) 0/328 Novel
. . 1/30 Novel
rs1227065 16 29/30 [5]
rs56181447 5 8/30 [5]
. . 1/30 [5]
rs1227051 16 28/30 [5]
rs17712523 8 7/30 [5]
rs3802711 10 16/30 [5]
rs74145660 3 6/30 [5]
rs11592462 6 8/30 [5]
rs10466026 12 26/30 [5]
rs41281334 1 (SR-1016) 3/128 [5]
rs4747194 12 26/30 [5]
rs4747195 12 26/30 [5]
. . 1/30 Novel
rs3802707 . 2/30 [5]
. 1 (SR-1016) 3/128 Novel
rs45583140 2 15/30 rs45583140
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mutation. Thus, p.Pro240Leu is the most common
cause of CDH23-associated ARNSHL in Asian popula-
tions. p.Glu1595Lys was present in 1 of 93 patients. Astuto
et al. reported that ~5% of recessive non-syndromic hear-
ing loss might be caused by mutation of CDH23 [6]. Al-
though GJB2 and SLC26A4 mutations were absent in our
patients, our results show that CDH23 mutation caused
ARNSHL in 2 of 13 (15%) affected Korean families and
that 3 of 93 patients with hearing loss carried a heterozy-
gous mutation. The precise frequency will be determined
by future mutation analysis of a large patient cohort, but is
estimated to be high. Therefore, CDH23, as well as GJB2
and SLC26A4, should be included in screening.
CDH23 (NM_22124) has 69 exons and encodes cadherin
23, a protein of 3,354 amino acids with 27 EC domains, a
single transmembrane domain, and a short cytoplasmic
domain [12]. It is a putative calcium-dependent adhesion
molecule required for proper morphogenesis of hair bun-
dles of inner ear neurosensory cells. Mutations in CDH23
cause the stereocilia of hair cells in the inner ear of Waltzer
mice (a model of USH1D) to become disorganized [13,14].
Many deafness mutations in CDH23 are in the calcium-
binding motif of the linker region between EC repeats. All
mutations detected in the present study were missense in
nature, and in the EC domain. Of the three mutations, two
(p.Glu1595Lys and p.Asn342Ser) affected highly conserved
EC calcium-binding sites (Figure 2B and D). The sites are
LDRE and DXNDN, and are thought to be essential for
linearization, rigidification, and dimerization of CDH23
[15,16]. The p.Glu1595Lys mutation may disrupt a con-
served LDRE calcium-binding motif in the fifteenth EC
domain. These EC domains are involved in cell-to-cell
adhesion via hemophilic calcium-dependent interactions
[16]. Molecular modeling of the p.Glu1595Lys mutation
shows impairment of calcium binding [17]. Since calcium
provides rigidity to the elongated structure of cadherin
molecules, thereby enabling hemophilic lateral interaction,
this mutation is likely to impair interactions of CDH23
molecules with either CDH23 or other proteins. Likewise,
the p.Asn342Ser mutation is also located in a highly con-
served EC calcium-binding site (DXNDN). Thus the
mutation probably decreases calcium affinity and im-
pairs protein function. Their pathogenic effects on pro-
tein structure or function are supported by in silico
analysis (Table 2).
Additionally, we identified 26 non-synonymous vari-
ants in the CDH23 coding exons from 16 hearing-loss
patients and 30 Korean control exomes (Table 3). Among
them, four variants have the potential to be pathogenic.
pGly266fs in SR-255S showed co-segregation in the family
and was absent in 128 Korean control exomes. However,
it was heterozygous, so we could not conclude that it is a
causative mutation. p.Asp428Asn in SR-68 was alsoheterozygous. DNA samples from family members were
not available. Thus, we could not confirm its pathogen-
icity by segregation analysis. p.Val2283Ile and p.Phe2801-
Val were identified as compound heterozygous mutations
in SR-1016. Co-segregation was confirmed by Sanger se-
quencing of family members, but these two variants were
detected in three of the 128 Korean control exomes. Thus,
we concluded that these two variants are not causative
mutations. However, a heterozygous mutation in a recessive
gene may be relevant to the hearing loss phenotype if it co-
exists with another heterozygous mutation [5], and it is a
low frequency in the general Korean population might not
rule out the possibility that it is pathogenic. Further exome
data accumulation and establishment of a database of com-
mon mutations in Korean patients with hearing loss will
help us to determine whether they are pathogenic or not.
We performed parallel sequencing of the whole exomes
of 13 small families and rapidly and successfully identified
the CDH23 mutation in two families. In two of the other
11 families, hearing loss was caused by the MYO15A mu-
tation [18], the first report of this mutation in Eastern
Asia. Whole-exome sequencing allowed us to screen mu-
tations in a large number of genes at the same time and to
detect pathogenic mutations in affected individuals who
were not identified by classical genetic studies. However,
the causative mutations in nine families have still not been
identified. In these families, whole-exome sequencing may
have missed some mutations in exons because it did not
completely cover the targeted region, which may have had
a high GC content or repetitive sequences, or because
hearing loss was caused by mutations an as-yet-unknown
gene. Our search for deafness genes in the remaining fam-
ilies is ongoing.Conclusions
We identified CDH23 mutations in two of 13 families with
ARNSHL by whole-exome sequencing. The exact fre-
quency will need to be determined in a future larger cohort
mutation analysis, but it is estimated to be high. Therefore,
as well as GJB2 or SLC26A4 screening, CDH23 should also
be considered. Our results show that whole-exome sequen-
cing is effective when used to detect causative mutations in
heterogeneous patients with hereditary hearing loss. In the
future, we anticipate the rapid discovery of hearing loss-
related genes by whole-exome sequencing, which will im-
prove understanding of the condition.Additional files
Additional file 1: Figure S1. Pedigrees of two families with ARNSHL,
and audiogram of patient SR-209. (A) Filled symbols in each pedigree
represent affected individuals. The proband is indicated by an arrow.
Asterisks indicate available samples. The two individuals whose exomes
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http://www.biomedcentral.com/1471-2350/15/46were sequenced are shown in red. (B) Audiogram of patient SR-209. No
audiogram is available for SR-106, only ABR data.
Additional file 2: Figure S2. Pedigrees of 11 families with ARNSHL. All
families comprised normally hearing parents and two affected siblings.
Asterisks indicate sequenced sample. Two (A and B) of 11 families had
causative MYO15A mutation [18]. In the other families (C-K), the causative
mutations in known deafness genes were not identified.
Additional file 3: Table S1. Results of exome sequencing in two
individuals with ARNSHL. Table S2. List of the 55 deafness genes that were
used to filter variants. Table S3. Candidate variants identified in this study.
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